Last reviewed · How we verify
Midodrine Hydrochloride Tablets
Midodrine is an alpha-1 adrenergic agonist that increases blood pressure by constricting blood vessels.
Midodrine is an alpha-1 adrenergic agonist that increases blood pressure by constricting blood vessels. Used for Orthostatic hypotension, Symptomatic hypotension.
At a glance
| Generic name | Midodrine Hydrochloride Tablets |
|---|---|
| Also known as | Gutron |
| Sponsor | Tehran Heart Center |
| Drug class | Alpha-1 adrenergic agonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Midodrine is a prodrug that is metabolized to desglymidodrine, its active metabolite, which selectively stimulates alpha-1 adrenergic receptors on arterioles and venules. This peripheral vasoconstriction increases both systolic and diastolic blood pressure, making it useful for treating conditions characterized by abnormally low blood pressure. The drug does not cross the blood-brain barrier significantly, limiting central nervous system effects.
Approved indications
- Orthostatic hypotension
- Symptomatic hypotension
Common side effects
- Hypertension
- Piloerection (goosebumps)
- Pruritus
- Supine hypertension
- Urinary retention
Key clinical trials
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia (PHASE4)
- Midodrine Effect on the Mortality Rates in Septic Shock Patients (PHASE2)
- Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension (PHASE2, PHASE3)
- Food Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg (PHASE1)
- Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg (PHASE1)
- Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg (PHASE1)
- Treatment Strategy of Vasovagal Syncope (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |